International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016
29 November 2016. Related: Conference reports.
HIV 13 Glasgow 2016
1000-fold mark-up for drug prices in high-income countries blocks access to HIV, HCV and cancer drugs
29 November 2016. Related: Conference reports, Treatment access.
Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses
29 November 2016. Related: Conference reports, Antiretrovirals.
Attachment inhibitor GSK-934/BMS-068: 96-week subgroup analysis in treatment-experienced patients
29 November 2016. Related: Conference reports, Antiretrovirals.
Once-weekly albuvirtide infusion: early results of T-20-like compound
29 November 2016. Related: Conference reports, Antiretrovirals.
Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not
29 November 2016. Related: Conference reports, Treatment strategies.
Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients
29 November 2016. Related: Conference reports, PK and drug interactions, TB coinfection.
Further reports of CNS-related side effects with dolutegravir
29 November 2016. Related: Conference reports, Side effects.
Generic PrEP bought online for UK use is validated by drug testing service
29 November 2016. Related: Conference reports, HIV prevention and transmission.
Immunology and HIV persistence – implications for a cure
29 November 2016. Related: Conference reports, Cure-related research.
Selected webcasts from Glasgow 2016
29 November 2016. Related: Conference reports.